12:14 PM
 | 
May 20, 2019
 |  BC Extra  |  Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

Editor's Note: This article was updated on May 20, 2019 at 2:35 PM PDT

Keytruda fails in previously treated TNBC
Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in the Phase III KEYNOTE-119 trial as second- or third-line treatment of metastatic triple-negative breast cancer.

Inclisiran shows sustained LDL-C lowering
Ahead of Phase III readouts expected in 3Q19 for inclisiran, The Medicines Co. (NASDAQ:MDCO) reported interim data from the...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >